Could a statin and arthritis drug tame childhood brain cancer?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed recurrent or progressive primary hypothalamic-chiasmatic low grade glioma, and not warranting a biopsy or surgery * Histologically confirmed recurrent or progressive primary hypothalamic-chiasmatic high grade glioma, or in complete remission after a new exeresis, excepted brainstem gliomas * Relapsed or refractory disease after at least 1 line adjuvant treatment including radiation therapy, but not surgery * Measurable lesions according to RANO criteria for the patients with low grade glioma and for the patients with high grade glioma included in RP2D level (Recommended Phase 2 Dose). * Non-measurable lesions according to RANO criteria for patients with high grade glioma included in the dose escalation step. * Age \> 6 years and \< 21 years old * Lansky score \> 70 or WHO score \< 2 (neurological conditions associated with the disease should not be taken into consideration) * Haematological conditions: ANC \> 1000/mm3 and platelets \> 75000/mm3 * Creatinine \< 1.5 x normal for age or calculated clearance \> 70 ml/mn/1.73m2 * Hepatic function: Total bilirubin \< 3 N and SGOT and SGPT \< 4 N * Muscle enzymes : CPK \< 2 N * No organ toxicity superior to grade 2 according to NCI-CTCAE v4.0 * No allergy, hypersensibility to one of the compounds of the treatment * Patients able to swallow capsules * Life expectancy at least \> 6 months for low grade gliomas and \> 3 months for high grade gliomas * Patient affiliated with a health insurance system * Effective contraception for patients (male and female) with reproductive potential throughout the treatment period * Written informed consent of patient and/or parents/guardians prior to the study participation Exclusion Criteria: * Chemotherapy within 21 days before D1 of experimental treatment. This period may be shortened in case of previous chemotherapy with vincristine (2 weeks), or extended in case of targeted therapies (4 weeks), or treatment by nitrosoureas (6 weeks) * Radiotherapy within 6 months before D1 of experimental treatment * Peptic ulcer disease, or gastrointestinal bleeding * Known hypersensitivity to sulfonamides. * History of asthma, acute rhinitis, nasal polyps, angioedema, urticaria or other allergic-type reactions induced by acetylsalicylic acid or NSAIDs , including COX-2 inhibitors (cyclo-oxygenase- 2) * Inflammatory bowel disease. * Known congestive heart failure (NYHA II- IV) * Ischemic proven, peripheral and/or history of arterial stroke (including transient ischemic attack) * Pregnancy or breast feeding woman * Known allergy to experimental treatment * Organ toxicity superior to grade 2 according to NCI-CTCAE v4.0 * Active infection * Pre-existing muscle pathology * Unsuitable for medical follow-up (geographic, social or mental reasons)